Aggressive Systemic Mastocytosis
📧 Sign up to get email alerts when something new happens for Aggressive Systemic Mastocytosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis [Phase 2]
Phase 2 PATHFINDER study evaluating avapritinib in advanced systemic mastocytosis and related subtypes has completed with results posted, as…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis [Phase 2]
Bezuclastinib is being studied in a Phase 2 trial for advanced systemic mastocytosis and related subtypes; recruitment is ongoing.
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The document reports expanded access for Bezuclastinib to patients with nonadvanced or advanced systemic mastocytosis.
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]
MacroGenics reports a Phase 1 study of MGD024 in relapsed or refractory hematologic malignancies is currently recruiting across multiple dis…
-
CLINICAL_TRIALS withdrawal · 2024-06-28Clinical Trial Update: Managed Access Programs for PKC412, Midostaurin
This update indicates that Novartis' managed access programs for midostaurin (PKC412) are no longer available, impacting access for patients…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-04-20FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for RYDAPT (midostaurin) from Novartis, updating the regulatory status of the product.
-
CLINICAL_TRIALS trial_result · 2019-01-29Clinical Trial Update: Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia [Phase 2]
Phase 2 trial evaluating Brentuximab vedotin in advanced systemic mastocytosis or mast cell leukemia has completed and results have been pos…
-
CLINICAL_TRIALS trial_result · 2018-09-20Clinical Trial Update: Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis [Phase 2]
Phase 2 trial of ibrutinib in advanced systemic mastocytosis was terminated with posted results in 2018.
-
FDA approval · 2018-06-21FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for RYDAPT (midostaurin) from Novartis Pharmaceuticals; the update expands or modifies the drug’s la…
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia [Phase 2]
Phase 2 trial update evaluating the efficacy and safety of midostaurin in patients with aggressive systemic mastocytosis or mast cell leukem…
-
CLINICAL_TRIALS trial_result · 2017-01-10Clinical Trial Update: Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
A clinical trial update on a patient-reported outcome questionnaire for systemic mastocytosis, with the study status marked as completed.
-
CLINICAL_TRIALS trial_result · 2015-07-09Clinical Trial Update: Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia [Phase 2]
Phase 2 trial update for midostaurin in aggressive systemic mastocytosis and mast cell leukemia has completed with results posted in 2015.